A clinical trial (NCT04538599) conducted by Yongxian et al. evaluated the efficacy of CD7 CAR T-Cell therapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) in 17 patients with relapsed/refractory (R/R) CD7-positive leukemia or lymphoma; none of the patients had previously undergone alloHSCT. Here, CD7 is linked to leukemia.